VIRAGEN EUROPE LTD
10-Q, EX-27, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: VIRAGEN EUROPE LTD, 10-Q, EX-11, 2000-11-14
Next: HEALTHSOUTH CORP, 10-Q, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2001
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       3,794,875
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             3,913,972
<PP&E>                                       5,112,701
<DEPRECIATION>                                 961,559
<TOTAL-ASSETS>                               8,065,114
<CURRENT-LIABILITIES>                          579,623
<BONDS>                                         17,781
                                0
                                          0
<COMMON>                                       245,864
<OTHER-SE>                                   3,116,849
<TOTAL-LIABILITY-AND-EQUITY>                 8,065,114
<SALES>                                              0
<TOTAL-REVENUES>                                64,017
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,570,199
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                             (1,506,182)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (1,506,182)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (1,506,182)
<EPS-BASIC>                                      (0.08)
<EPS-DILUTED>                                    (0.08)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission